intraven carboplatin recurr malign glioma phase II studi thirti patient recurr malign glioma intraven IV carboplatin cbdca week dose patient recurr tumor prior radiotherapi prior chemotherapi assess patient treatment week stabl diseas progress diseas total respons respons rate median time progress mtp week patient mtp patient week toxic effect hematolog thrombocytopenia granulocytopenia dose neurotox renal toxic result cbcda week activ patient recurr malign glioma hematolog toxic mild dose respons rate 